Biosenta Inc.
ZRO
CNSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -42.86% | 24,366.67% | -40.00% | -33.33% | -22.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -42.86% | 24,366.67% | -40.00% | -33.33% | -22.22% |
| Cost of Revenue | -83.33% | -98.11% | -87.45% | -87.39% | -87.39% |
| Gross Profit | 113.04% | 666.02% | 90.43% | 90.00% | 90.00% |
| SG&A Expenses | -25.79% | -13.96% | 11.97% | 36.73% | 23.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.33% | -14.10% | 10.38% | 25.90% | 15.37% |
| Operating Income | 26.34% | 28.08% | -10.41% | -25.95% | -15.41% |
| Income Before Tax | 65.11% | -1,449.37% | -1,060.69% | -422.54% | -295.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 65.11% | -1,449.37% | -1,060.69% | -422.54% | -295.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.11% | -1,449.37% | -1,060.69% | -422.54% | -295.28% |
| EBIT | 26.34% | 28.08% | -10.41% | -25.95% | -15.41% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 60.69% | -501.07% | -447.38% | -381.99% | -215.50% |
| Normalized Basic EPS | -29.93% | 0.32% | -19.12% | -10.39% | 26.15% |
| EPS Diluted | 60.69% | -501.07% | -447.38% | -381.99% | -215.50% |
| Normalized Diluted EPS | -29.93% | 0.32% | -19.12% | -10.39% | 26.15% |
| Average Basic Shares Outstanding | 9.69% | 38.55% | 31.92% | 31.64% | 33.32% |
| Average Diluted Shares Outstanding | 9.69% | 38.55% | 31.92% | 31.64% | 33.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
